Junshi Biosciences Announces FDA Expanded Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Individuals under the Age of 12
December 05, 2021 18:06 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 06, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Junshi Biosciences Announces Two Additional Indications for Toripalimab Included in China’s National Reimbursement Drug List
December 03, 2021 07:53 ET
|
Junshi Biosciences
SHANGHAI, China, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Junshi Biosciences Announces Approval of Supplemental New Drug Application by NMPA for Toripalimab in Combination with Cisplatin and Gemcitabine as First-Line Treatment for Patients with Locally Recurrent or Metastatic Nasopharyngeal Carcinoma
November 29, 2021 20:00 ET
|
Junshi Biosciences
SHANGHAI, China, Nov. 30, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the National Medical Products...
Junshi Biosciences and Coherus Announce Toripalimab Granted Orphan Drug Designation in the United States for Esophageal Cancer
November 15, 2021 08:30 ET
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences,...
TopAlliance Appoints Virginia Ellen Maher, MD, as Vice President of Medical Sciences
November 01, 2021 08:00 ET
|
Junshi Biosciences
SHANGHAI, China, Nov. 01, 2021 (GLOBE NEWSWIRE) -- TopAlliance Biosciences, a wholly own subsidiary of Junshi Biosciences (HKEX: 1877; SSE: 688180) today announced the appointment of Dr. Virginia...
Junshi Biosciences and Coherus Announce FDA Acceptance of BLA Filing for Toripalimab for Treatment of Nasopharyngeal Carcinoma
November 01, 2021 07:30 ET
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc....
Junshi Biosciences Announces Expansion of Emergency Use Authorization for Etesevimab and Bamlanivimab Administered Together to Include Post-Exposure Prophylaxis for COVID-19
September 19, 2021 07:29 ET
|
Junshi Biosciences
SHANGHAI, China, Sept. 19, 2021 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and...
Junshi Biosciences and Coherus to Present Positive Progression Free Survival and Overall Survival Results from JUPITER-06, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma
September 16, 2021 20:19 ET
|
Junshi Biosciences
– Interim results to be presented September 17 at the European Society for Medical Oncology (ESMO) Congress 2021 – – Data support the use of toripalimab with chemotherapy as first-line therapy...
Junshi Biosciences and Coherus Announce Results from Phase 3 Study of Toripalimab Published in September Issue of Nature Medicine
September 15, 2021 08:30 ET
|
Junshi Biosciences
SHANGHAI and REDWOOD CITY, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”,...
Positive Interim Results of CHOICE-01 Study Evaluating Junshi Biosciences and Coherus’ Toripalimab for First Line Treatment of Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
September 13, 2021 20:55 ET
|
Junshi Biosciences
SHANGHAI, China and REDWOOD CITY, Calif., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus Biosciences, Inc....